Table 2.
Microbiological parameters in Treatment Group I patients (N = 23).
| Post-Systemic Metronidazole Plus Ciprofloxacin |
|||
|---|---|---|---|
| Microbial Species | Baseline | 1 Month Post-Treatment |
1 Year Post-Treatment |
| Periodontal Pathogens: | |||
| Aggregatibacter actinomycetemcomitans | 6 (0.2) § | 0 § | 1 (0.1) § |
| Porphyromonas gingivalis | 5 (6.8) | 0 | 1 (4.4) |
| Prevotella intermedia/nigrescens | 9 (11.1) | 4 (3.1) | 4 (3.7) |
| Parvimonas micra | 16 (12.0) | 4 (2.4) | 6 (8.6) |
| Campylobacter rectus | 21 (3.7) | 12 (0.6) | 9 (1.1) |
| Superinfecting Species: | |||
| enteric rods/pseudomonads | 17 (20.3) § | 2 (0.5) § | 3 (0.5) § |
| staphylococci | 0 | 3 (1.4) | 1 (1.1) |
| Enterococcus faecalis | 0 | 0 | 0 |
| Candida species | 4 (0.1) | 4 (3.4) | 3 (0.8) |
| Mean % total recovery of test periodontal pathogens and superinfecting species (SD) † | 22.9 (18.2) | 0.9 (1.7) * | 2.4 (3.2) * |
| No. (%) of patients with high-risk subgingival microbiota ‡ | 23 (100) | 3 (13.0) * | 3 (13.0) * |
| Mean % recovery of viridans streptococci (SD) | 2.6 (1.5) | 24.2 (21.7) * | 27.9 (22.2) * |
§ No. of culture-positive patients (mean percent CFU recovery of test species among total subgingival viable counts in species-positive patients), † Total cultivable subgingival proportions of the selected species among total viable subgingival anaerobic counts per patient, ‡ Defined as cultivable presence of either A. actinomycetemcomitans and/or P. gingivalis, and/or cultivable recovery of P. intermedia/nigrescens at ≥2.5%, P. micra at ≥3.0%, C. rectus at ≥2.0%, and/or either Gram-negative enteric rods/pseudomonads, staphylococci, or Candida species at ≥5.0%, of total subgingival viable counts, * Significantly different from baseline (p < 0.05).